Evidence supporting the use of: Proteinase inhibitor
For the health condition: Infection (viral)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Proteinase inhibitors are scientifically validated agents in the treatment of viral infections, particularly in the context of HIV and hepatitis C virus (HCV) infections. These inhibitors target viral proteases—enzymes essential for processing viral polyproteins into functional proteins required for viral replication. Inhibiting these proteases disrupts the viral life cycle, thereby reducing viral load and disease progression.

The most prominent use of proteinase inhibitors is in highly active antiretroviral therapy (HAART) for HIV infection. Drugs such as ritonavir, lopinavir, and darunavir are potent HIV protease inhibitors and are foundational components of combination therapies. Their efficacy has been demonstrated in numerous randomized controlled trials and has led to significant improvements in morbidity and mortality among HIV-infected individuals.

Similarly, direct-acting antiviral agents for HCV, such as simeprevir and grazoprevir, inhibit the NS3/4A protease of the hepatitis C virus, achieving high rates of sustained virological response in patients. The development and approval of these medications are grounded in robust clinical evidence, including large-scale phase III clinical trials.

While proteinase inhibitors have not been broadly effective against all viral infections (e.g., they are not used for influenza or common cold viruses), their role in HIV and HCV therapy is well established and supported by extensive scientific literature.

More about proteinase inhibitor
More about Infection (viral)

Products containing proteinase inhibitor

We currently have no products on Caring Sunshine that contain this ingredient.